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gomery-Asberg Depression Rating Scale, the Brief Psychiatric Rating 
Scale and the SLE Disease Activity Index (SLEDAI)  [6] . Because of 
their clinical specificity, the CRS and the SLEDAI were the primary 
variables. For the comparison of pre- and postclinical scores, we used 
a nonparametric test which needs a minimum of 5 patients to reach 
a 0.05 significance.
 During the course of the study, 5 patients were admitted with SLE 
and catatonia. These 5 patients, all female, met the inclusion criteria. 
All of them (or their families on their behalf) agreed to PE. Three of 
the patients were teenagers who had been hospitalized for several 
weeks without any improvement, receiving a treatment regimen 
combining psychotropic medications, corticoids and immunosup-
pressors. Three patients exhibited life-threatening complications: 2 
were severely malnourished and the third had a pulmonary infection 
and skin lesions due to immobility. One patient showed a severe renal 
involvement. The last patient was included because of resistance after 
3 weeks of treatment.
 Table 1 summarizes the demographic, clinical and biological 
characteristics, and treatments of all subjects both before and after 
PE. All patients had severe depression with psychotic and catatonic 
features. The number of catatonic signs ranged from 6 to 12, with 
staring, negativism and withdrawal being present in all 5 patients, 
and catalepsy, stupor, mutism and refusal to eat in 4. Regarding SLE, 
the clinical and biological manifestations varied across individuals 
and included asthenia (n = 5), polyarthralgia (n = 3), renal involve-
ment (n = 3), cutaneous lesions (n = 3), weight loss (n = 2), myalgia
(n = 1), generalized adenopathy (n = 1) and melena (n = 1). One pa-
tient had an abnormal neurological examination limited to moderate 
ataxia. All patients had biological features of SLE. Routine biological 
and hematological tests showed anemia (n = 3), thrombocytopenia 
(n = 2), lymphopenia (n = 2) and proteinuria (n = 3). The cerebrospi-
nal fluid showed biochemical abnormalities in 3 patients but none of 
them had monoclonal immunoglobulin G or cell increase. MRI scans 
showed abnormalities in 3 patients, including cortical atrophy (n = 
2) and T 2 -weighted hyperintensities of the frontal lobes (n = 1).
 The mean number of PE that patients received was 7.2 (range: 
3–11). We found a significant improvement for all clinical variables. 
Mean CRS and SLEDAI scores before PE were 15 (range: 11–16) and 
18.8 (range: 12–22), respectively. Both scores dramatically decreased 
after PE to a mean of 1.2 (range: 0–6) and 3.4 (range: 0–12), respec-
tively (Wilcoxon paired test: Z = –2.032, p = 0.042). In particular, 3 
patients very much improved on the Clinical Global Impression Scale 
after the first week of PE. The biological variables paralleled clinical 
improvement. At follow-up, 4 patients were still doing well; in par-
ticular, all the teenagers were able to return to school with minimal 
treatment for SLE. The last patient (case 4) died in her local hospital 
as a consequence of a septic shock 3 months after discharge.
 To date, only a few case studies have reported the possible use of 
PE in neuropsychiatric SLE [7, 8], but catatonia was not explored. 
Therapeutic approaches to catatonia are mainly symptomatic. It is 
recommended (a) to use high doses of benzodiazepines or sedative 
drugs, and (b) to apply ECT in case of resistance or life-threatening 
conditions  [1] . However, treatment of associated disorders may im-
prove psychomotor symptoms as well. This is important when there 
are organic causes. Therefore, etiopathogenic investigations are 
mandatory when catatonia occurs  [9] . In the cases studied here, ben-
zodiazepines were inefficient, and ECT was not considered because 
of the associated SLE. The report that PE was an efficient treatment 
option for pediatric autoimmune neuropsychiatric disorders associ-
 Catatonia is a rare but severe psychiatric condition. The most fre-
quent causes are psychiatric diseases (e.g. schizophrenia), but organ-
ic causes should be considered as well (e.g. Wilson’s disease)  [1] . The 
recommended treatments are symptomatic and include the use of 
sedative drugs and electroconvulsive therapy (ECT)  [1] . Although 
rare cases of catatonia have been described in systemic lupus erythe-
matosus (SLE)  [2] , catatonia was not included in the recent nomen-
clature of neuropsychiatric SLE  [3] . In a recent report, we showed that 
plasma exchanges (PE) could be an efficient treatment option for 
catatonic manifestations of SLE, avoiding the use of ECT  [4] . The aim 
of the present study was to assess the efficacy of PE for severely resis-
tant patients with catatonia and SLE in an open trial.
 The consecutive patients were recruited at Pitié-Salpêtrière Hos-
pital from 2001 to 2004. For inclusion, the diagnosis of SLE was based 
on the revised criteria of the American College of Rheumatology  [3] . 
The diagnosis of catatonia was made based on at least two catatonic 
motor signs, or one catatonic motor sign (catalepsy, stupor, postur-
ing, waxy flexibility, staring, stereotypies, psychomotor excitement, 
automatic compulsive movements, muscular rigidity, echopraxia) 
combined with a nonmotor catatonic symptom indicative of severely 
impaired behavioral and emotional functioning (withdrawal, mut-
ism, mannerism, echolalia, incontinence, verbigeration, refusal to 
eat)  [5] . Clinical examinations by a psychiatrist and a physician spe-
cializing in internal medicine were repeated as needed. Psychiatric 
diagnoses were based on DSM-IV criteria. Additional investigations 
always included routine hematological tests, immunological investi-
gations, studies of cerebrospinal fluid, electroencephalography, and 
neuroimaging. All patients received a symptomatic psychiatric treat-
ment (benzodiazepine for motor symptoms, antidepressant for de-
pression, atypical neuroleptic for psychosis and mood stabilizer for 
bipolarity) combined with (a) high-dose intravenous methylpredni-
sone (1 g/day  ! 3) followed by oral prednisone (1 mg/kg/day), and (b) 
monthly pulse cyclophosphamide (0.7 g/m 2 ) or azathioprine (2–
3 mg/kg/day). In case of life-threatening conditions, severe complica-
tions of SLE or resistance to pharmacotherapy for 3 weeks, patients 
were asked to receive PE and written consent was obtained (from 
them or their families). PE (60 ml/kg) was given 2–3 times per week. 
Treatment efficacy was monitored using the Clinical Global Impres-
sion-Severity Scale, the Global Assessment of Functioning Scale, the 
modified Bush-Francis Catatonia Rating Scale (CRS)  [5] , the Mont-
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ated with streptococcal infections  [10] suggested that neuropsychiat-
ric symptoms related to immune dysfunction – such as SLE – could 
be improved by an immunomodulatory treatment as well. In this se-
ries, the dramatic clinical improvement following PE in all patients 
suggests that the use of PE, combined with high-dose steroids and 
cyclophosphamide pulses, may be an efficient treatment option in 
SLE-related catatonia. However, more research is needed to defini-
tively establish PE as an efficient treatment option in SLE-related 
catatonia.
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Table 1. Clinical characteristics and efficacy of PE in 5 patients with SLE and catatonia
Variable Case 1 Case 2 Case 3 Case 4 Case 5
Age, years 15 17 16 41 47
Gender F F F F F
Duration of SLE, months 6 36 12 24 120 
DSM-IV diagnosis MDE-psychotic MDE-psychotic MDE-psychotic MDE-psychotic MDE-psychotic
Clinical variables Pre-PE Post-PE Pre-PE Post-PE Pre-PE Post-PE Pre-PE Post-PE Pre-PE Post-PE
CGI-S1 7 2 7 3 7 3 7 5 7 3
GAF1 21 72 20 65 15 59 21 40 21 90
MADRS1 46 0 40 20 39 13 47 36 50 6
CRS1 16 0 16 0 18 0 14 6 11 0
BPRS1 64 20 46 23 52 24 65 49 57 19
SLEDAI1 20 0 12 3 22 0 20 12 20 2
Biological variables
Antinuclear antibody2 10,000 640 5,120 1,280 5,120 1,280 2,560 640 2,560 320
Anti-DNA antibody2 12 <4 5 <4 <4 <4 23 27 68 <4
C32 0.65 0.83 0.99 0.78 1.14 0.95 0.85 0.43 0.62 0.79
Antiribosomal P antibody2 1,290 <15 1 1 1 2 900 300 13 2
CSF NL NL IgG PROT GLUC
Treatment regimen
PE 6 6 10 11 3
Pulse cyclophosphamide yes yes yes no no/azathioprine
Steroids yes yes yes yes yes
Hydroxychloroquine yes no yes no yes










Variables at follow-up 2 years 1 year 1 year 3 months 4 years
CGI-S 1 2 1 dead 2
GAF 90 73 85 80
SLEDAI 0 0 0 0
MDE-psychotic = Major depressive episode with psychotic features; CGI = Clinical Global Impression Scale; MADRS = Montgomery-Asberg Depres-
sion Rating Scale; BPRS = Brief Psychiatric Rating Scale; C3 = complement fraction 3; NL = normal; PROT = z proteins; IgG = z polyclonal immuno-
globulin G; GLUC = z glucose.
1 p < 0.05 (Wilcoxon paired test). 2 Post-PE values of biological variables correspond to values measured 1 month after the last PE.
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